Advertisement
 
YOU ARE HERE: LAT HomeCollectionsMiragen Inc
IN THE NEWS

Miragen Inc

MORE STORIES ABOUT:
FEATURED ARTICLES
BUSINESS
November 25, 1997 | (Times Staff and Wire Reports)
InVitro International said Monday that it has revised its merger agreement with privately held Miragen Inc. of Irvine, so that InVitro shareholders will receive 10% of the common stock of the combined company after the deal is completed. The agreement still must be approved by directors of both companies. Miragen manufactures and markets biological testing products for human and animal identification in various clinical laboratory, hospital, animal and forensic applications.
ARTICLES BY DATE
BUSINESS
November 25, 1997 | (Times Staff and Wire Reports)
InVitro International said Monday that it has revised its merger agreement with privately held Miragen Inc. of Irvine, so that InVitro shareholders will receive 10% of the common stock of the combined company after the deal is completed. The agreement still must be approved by directors of both companies. Miragen manufactures and markets biological testing products for human and animal identification in various clinical laboratory, hospital, animal and forensic applications.
Advertisement
BUSINESS
May 16, 1997 | E. SCOTT RECKARD, TIMES STAFF WRITER
Reporting the latest in a 12-year string of losses, toxic-testing specialist InVitro International said Thursday it plans to merge with an allied private company, Miragen Inc., which will wind up owning 80% of the new company. InVitro also announced Thursday that the Nasdaq Small Cap Market will no longer list its stock because its assets have fallen below $2 million. The stock, which closed unchanged Thursday at 18.75 cents, will trade over the counter.
BUSINESS
May 16, 1997 | E. SCOTT RECKARD, TIMES STAFF WRITER
Reporting the latest in a 12-year string of losses, toxic-testing specialist InVitro International said Thursday it plans to merge with an allied private company, Miragen Inc., which will wind up owning 80% of the new company. InVitro also announced Thursday that the Nasdaq Small Cap Market will no longer list its stock because its assets have fallen below $2 million. The stock, which closed unchanged Thursday at 18.75 cents, will trade over the counter.
BUSINESS
May 16, 1997 | E. SCOTT RECKARD, TIMES STAFF WRITER
Reporting the latest in a 12-year string of losses, toxic-testing specialist InVitro International said Thursday that it plans to merge with an allied private company, Miragen Inc., which will wind up owning 80% of the new company. InVitro also announced Thursday that the Nasdaq SmallCap Market will no longer list its stock because its assets have fallen below $2 million. The stock, which closed unchanged Thursday at 18.75 cents, will trade over the counter.
BUSINESS
March 13, 1996
InVitro International, which makes products that test toxic levels in substances, said Tuesday that it will broaden its market by licensing a product from another Irvine drug company. InVitro will have the exclusive rights to market a Miragen Inc. product called Guardian DNA that helps to identify any living organism. Miragen will receive exclusive supply rights and future considerations. Financial details were not disclosed.
CALIFORNIA | LOCAL
January 22, 1991 | LINDA ROACH MONROE, TIMES STAFF WRITER
The military will use a high-tech test developed by a San Diego company to assure that all the available body parts from each Gulf War fatality are placed in the proper casket for burial. This grisly task of identifying dismembered bodies will be performed at the military's mortuary, at Dover Air Force Base in Delaware.
BUSINESS
June 21, 1998 | WALTER HAMILTON, TIMES STAFF WRITER
To individual investors, the Internet is nothing short of a godsend. It lets them easily gather financial information, swap investment ideas and track their holdings. Unfortunately, the Internet also has opened up a potentially limitless venue for the promotion of extremely risky penny stocks.
BUSINESS
May 16, 1997 | E. SCOTT RECKARD, TIMES STAFF WRITER
Reporting the latest in a 12-year string of losses, toxic-testing specialist InVitro International said Thursday that it plans to merge with an allied private company, Miragen Inc., which will wind up owning 80% of the new company. InVitro also announced Thursday that the Nasdaq SmallCap Market will no longer list its stock because its assets have fallen below $2 million. The stock, which closed unchanged Thursday at 18.75 cents, will trade over the counter.
Los Angeles Times Articles
|